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Objectives: In this study the efficacy of doripenem, a new broad-spectrum carbapenem, was tested against an
Escherichia coli strain and a Klebsiella pneumoniae strain in an experimental animal model. The comparator
was cefepime monotherapy.
Methods: The rabbit meningitis model was used in this study and the penetration of doripenem through
uninflamed and inflamed meninges was determined.
Results: Doripenem, injected three times (75 mg/kg), led to serum peak levels around 100 mg/L and trough
levels around 5 mg/L, resulting in a penetration rate of 14% through inflamed meninges and 7% through
uninflamed meninges. Against K. pneumoniae, doripenem was slightly but not significantly more efficacious
than cefepime over 8 h (5.40+1.37 log10 cfu/mL versus 3.59+0.89 log10 cfu/mL for cefepime). Also against
the E. coli strain doripenem was slightly superior to the comparator (5.55+0.87 log10 cfu/mL versus
3.80+1.10 log10 cfu/mL for cefepime), although the difference was not significant.
Conclusions: Doripenem is a potential monotherapy for the treatment of meningitis due to Gram-negative
microorganisms.
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Introduction
The treatment of serious infections has been increasingly com-
promised by the continuous emergence of Gram-negative and
Gram-positive resistant nosocomial pathogens.1,2 Antibiotics
sharing the carbapenem ring are attractive candidates in the
empirical treatment of nosocomial infections because of their
broad antimicrobial spectrum. In general, carbapenems
harbour a high efficacy against the major Gram-negative and
Gram-positive pathogens, except against Enterococcus faecium
and oxacillin-resistant staphylococci.3–5
Doripenem is a new 1-b-methyl-carbapenem with a specific
side chain substitution increasing its activity against non-
fermentative Gram-negative microorganisms.6 In addition,
doripenem is not hydrolysed by renal dehydropeptidases and
stable to common b-lactamases, including extended-spectrum
b-lactamases (ESBLs).7
Doripenem has been widely used in the treatment of
nosocomial infections. It has beenapprovedby the EuropeanMed-
icines Agency for the treatment of nosocomial pneumonia
including ventilator-associated pneumonia, complicated
intra-abdominal infections and complicated urinary tract
infections including pyelonephritis. In the USA it has been
approved by the US FDA for complicated intra-abdominal infec-
tions and complicated urinary tract infections including
pyelonephritis.8
However, little is known about the penetration of doripenem
into the CSF. In the experimental rabbit meningitis model, we
have already determined the penetration of two other common-
ly used carbapenems, i.e. meropenem and ertapenem, and we
have tested their efficacy in meningitis due to penicillin-resistant
pneumococci.9,10
The aim of this study was to test the efficacy of doripenem in
experimental meningitis against two Gram-negative pathogens,
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i.e. Klebsiella pneumoniae and Escherichia coli, and to determine
its penetration through inflamed and uninflamed meninges.
Materials and methods
Strains and antibiotics
K. pneumoniae (1173687) and E. coli (QK-9) were kindly provided by the
Institute for Infectious Diseases, University of Bern. Both strains were
grown in Mueller–Hinton broth. Doripenem was provided by Johnson &
Johnson Company, USA, and cefepime was commercially purchased.
Experimental meningitis model
The experimental rabbit meningitis model described by Dacey and
Sande11 was used in this project. The experimental protocols were
approved by the Kantonales Veterina¨ramt des Kantons Bern. Pathogen-
free New Zealand rabbits were provided by the Zentraltiersta¨lle der Med-
izinischen Fakulta¨t der Universita¨t Bern, where all the experiments were
performed.
One day before an experiment, rabbits were anaesthetized with intra-
muscular injections of ketamine (30 mg/kg) and xylazine (15 mg/kg), and
fitted with prostheses on their calvarium to facilitate subsequent place-
ment within a stereotactic frame. On the day of the experiment,
rabbits received 1.75 g/kg ethylcarbamate (urethane) by subcutaneous
injection and then 10 mg/kg pentobarbital by intravenous (iv) injection
to induce deep anaesthesia. The animals were fixed in a stereotactic
frame, and a 3.5 inch (25G) spinal needle was introduced into the cis-
terna magna. Following the withdrawal of 0.2 mL of CSF, the test bacteria
(1×105 cfu in 0.2 mL of saline solution) were injected into the subarach-
noid space. After inoculation the animals were brought back to their
cages for the night. The next day the rabbits were again fitted in the
frames using the techniques and anaesthesia described above. A cath-
eter was fixed in the femoral artery for serum sampling. A spinal
needle was fixed again in the subarachnoid space. Doripenem was
injected (75 mg/kg iv) at hours 0, 3 and 6 because of its short half-life
in rabbits. The comparator regimen, cefepime (100 mg/kg), was injected
at hours 0 and 4, as previously described.12,13
CSF (0.2 mL) was sampled at 0, 1, 2, 4, 6 and 8 h after infection. Blood
was sampled at 0.25, 0.5, 1, 2, 3, 4, 4.25, 4.5, 5, 6, 7 and 8 h. Each experi-
mental series included untreated control rabbits. In each group 10
rabbits were treated.
Determination of antibiotic levels and cfu titres
The doripenem concentration in serum and CSF, and the cefepime con-
centration in the CSF were determined by diffusion microbioassays
using agar plates containing Bacillus subtilis (sus-1-A), 106 cfu/0.1 mL
(Raven Biological Laboratories, Inc.).14,15
cfu were determined by serial dilution of CSF. Samples thereof (20 mL)
were plated on agar plates and incubated overnight at 378C. The limit of
detection of this assay was therefore 50 cfu/mL (1.7 log10/mL).
The penetration into the CSF was determined by comparing areas
under the curves (AUCs) for serum and CSF using GraphPad Prism Soft-
ware, version 5.0 (GraphPad Software Inc., San Diego, CA, USA).
Statistical analysis
Student’s t-test and one-way analysis of variance (Tukey–Cramer mul-
tiple comparisons test) were used for parametric data. Comparison of
positive and negative cultures was analysed by the two-tailed Fisher
exact test (GraphPad Prism Software, version 5.0). A P value ,0.05 was
considered significant.
The efficacy of the different regimens is presented as Dlog10 cfu/mL/h
and as Dlog10 cfu/mL/8 h.
A value of 1.7 log10 cfu/mLwas assigned to the first sterile CSF sample
and a value of 0 to each following sterile CSF sample.
Results
The kinetic properties of doripenem are presented in
Figure 1(a and b). Due to its short half-life, doripenem had to
be injected three times (3×75 mg/kg). At 15 min after the first
injection, doripenem peaked at about 100 mg/L in the serum,
but decreased rapidly to 2 mg/L 2 h later. The second injection
led to similar peak levels that decreased again before the third
injection. The effect of the third injection was comparable. In
the inflamed CSF, the levels increased progressively after the
first injection, with peak levels around 10 mg/L, decreasing to
2 mg/L before the next injection. After the second injection,
CSF levels increased again to around 10 mg/L and decreased
again by the same order of magnitude. At the end of the experi-


























































Figure 1. (a) Serum and CSF levels of doripenem after three iv injections
of 75 mg/kg. The filled squares represent serum levels and open squares
represent CSF levels. Results are expressed as means+SD. (b) CSF levels
of doripenem through inflamed meninges (filled squares) and through




In non-infected rabbits (uninflamed meninges) the CSF levels
were about 1 mg/L during the first 4 h and increased progressive-
ly to 5 mg/L after the third injection. The kinetics of doripenem
through uninflamed and inflamed meninges is shown in
Figure 1(b). The penetration of doripenem through inflamed
meninges was 14+3.4% and 7+0.68% through uninflamed
meninges, determined by comparison of AUCs (GraphPad Prism
Software, version 5.0).
The penetration of cefepime into the CSF has been studied
previously.13 In the present study only CSF concentrations of
cefepime were measured, ranging between 10 and 15 mg/L.
The first injection led to levels around 10 mg/L, and after the
second injection cefepime levels peaked at 16 mg/L, decreasing
slowly to 14 mg/L at the end of the experimental period (data
not shown).
The MICs of both antibiotics were identical for the two strains,
i.e. 0.12 mg/L for E. coli and 0.25 mg/L for K. pneumoniae.
Figure 2(a and b) reflects the kinetics of the killing activity of
the different regimens. Against K. pneumoniae, doripenem
produced a more rapid decrease in the bacterial titre over 8 h
than the comparator. The antibacterial activity of the different
regimens is summarized in Table 1. The efficacy is expressed as
killing rate per hour and killing rate per 8 h (i.e. at the end of
the experimental period). Against K. pneumoniae, doripenem
produced a higher but marginally significant decrease per hour
of the viable cell count than cefepime (20.73+0.19 log10 cfu/mL
versus20.48+0.09log10 cfu/mL). At the end of the experimental
period the antibacterial activity of doripenem was slightly but not
significantly superior to cefepime (25.40+1.37 log10 cfu/mL
versus 23.59+0.89 log10 cfu/mL).
Against E. coli, doripenem produced a similar antibacterial
activity, with a killing rate per hour around 20.73 log10 cfu/mL
and 25.55 log10 cfu/mL over 8 h. In this experimental setting,
doripenem was not significantly superior to cefepime over 8 h
(killing rate of cefepime over 8 h¼23.80 log10 cfu/mL). Only
the killing rate per hour was significantly superior (killing rate of
cefepime per hour¼20.47 log10 cfu/mL).
At the end of the experimental period, the CSF samples for 5
of 10 rabbits infected with K. pneumoniae in the doripenem
group were sterile versus 2 of 10 in the comparator group.
Against E. coli, the difference in the decrease in the viable cell





























































Figure 2. (a) Decrease in the bacterial titre of E. coli after three injections
of 75 mg/kg doripenem (open squares) and after two injections of
100 mg/kg cefepime (filled squares). Results are expressed as
means+SD. The broken line represents the limit of detection of
bacteria in the CSF (1.7 log10 cfu/mL). (b) Decrease in the bacterial titre
of K. pneumoniae after three injections of 75 mg/kg doripenem (empty
squares) and after two injections of 100 mg/kg cefepime (filled
squares). Results are expressed as means+SD. The broken line
represents the limit of detection of bacteria in the CSF (1.7 log10 cfu/mL).
Table 1. Antibacterial activity of the different regimens
Group (n) Strain Inoculum at 0 h DKilling/h DKilling/8 h
Control (10) K. pneumoniae 6.02+0.30 log10 cfu/mL +0.12+0.02 log10 cfu/mL +1.02+0.22 log10 cfu/mL
Doripenem (10) K. pneumoniae 6.37+0.63 log10 cfu/mL 20.73+0.19 log10 cfu/mL
a 25.40+1.37 log10 cfu/mL
b
Cefepime (10) K. pneumoniae 5.79+0.83 log10 cfu/mL 20.48+0.09 log10 cfu/mL
a 23.59+0.89 log10 cfu/mL
b
Control (10) E. coli 5.95+0.23 log10 cfu/mL +0.11+0.05 log10 cfu/mL +0.92+0.37 log10 cfu/mL
Doripenem (10) E. coli 6.07+0.57 log10 cfu/mL 20.73+0.12 log10 cfu/mL
c 25.55+0.87 log10 cfu/mL
d
Cefepime (10) E. coli 5.96+0.38 log10 cfu/mL 20.47+0.14 log10 cfu/mL
c 23.80+1.10 log10 cfu/mL
d
aTukey–Kramer multiple comparisons test; doripenem versus cefepime: P,0.05.
bTukey–Kramer multiple comparisons test; doripenem versus cefepime: P.0.05, not significant.
cTukey–Kramer multiple comparisons test; doripenem versus cefepime: P,0.05.
dTukey–Kramer multiple comparisons test; doripenem versus cefepime: P.0.05, not significant.
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At the end of the experimental period, doripenem managed to
sterilize 7 of 10 CSF samples versus 2 of 10 for cefepime.
Discussion
The treatment of nosocomial infections caused by Gram-
negative and Gram-positive pathogens remains a major chal-
lenge for clinicians and infectiologists, especially since increasing
resistance of common clinical pathogens has limited the choice
of therapeutic options. In general, carbapenems are the pre-
ferred empirical treatment for the usual nosocomial pathogens
because of their extended spectrum.
Doripenem is a new member of the carbapenem class of
b-lactam antibiotics, with a spectrum of activity against Gram-
positive and Gram-negative pathogens, similar to meropenem
and imipenem. Against wild-type Pseudomonas aeruginosa,
doripenem may be slightly more efficacious than the other
carbapenems.16
In our meningitis rabbit model we tested the efficacy of
doripenem against two Gram-negative microorganisms
(K. pneumoniae and E. coli) and measured its penetration into
the CSF. The comparator regimen was cefepime. The MICs of the
two antibiotics were identical for both bacterial strains. In our
experimental model, doripenem had to be injected three times
(3×75 mg/kg) due to its very short half-life in rabbits. In
humans, the half-life of doripenem is about 1 h.8 In our study,
each injection of doripenem led to a peak serum level of about
100 mg/L, which decreased rapidly to 2 mg/L 2 h later. The CSF
levels fluctuated between 10 and 2 mg/L, with a level around
7 mg/L at the end of the experimental period. Despite higher
serum peak levels, 75 mg/kg of doripenem injected three times
during 8 h mimics approximately the kinetics of one injection of
500 mg in humans.17 The CSF penetration of doripenem into
inflamed meninges was 14%, comparable to meropenem, but
higher than ertapenem (7%).10,18 The penetration of doripenem
into non-inflamed meninges (uninfected animals) was about
7%. During the first 4 h the CSF levels remained low (between 1
and 2 mg/L), but increased for unknown reasons during the
second part of the experimental period, with a peak level at
about 6 mg/L (see Figure 1b). Cefepime injected twice
(2×100 mg/kg) led to CSF levels between 10 and 15 mg/L,
similar to levelsmeasured in previous studies.12,13The penetration
of cefepime into the CSF of rabbits as determined in previous
studies ranged between 16% and 22%.19,20 Based on their ap-
proximately similar CSF levels and their identical MICs for the
two pathogens, comparable CSF level/MIC ratios could be
expected for the two antibiotics. The CSF peak level/MIC ratio
was 83 for doripenem and 125 for cefepime against E. coli and
40 for doripenem and 60 for cefepime against K. pneumoniae, re-
spectively. In this study, timeover theMIC (T.MIC)wasnotagood
discriminating parameter because it was 100% for both
antibiotics.
According to their similar CSF levels, MICs and CSF level/MIC
ratios, a comparable antibacterial efficacy could be assumed for
doripenem and cefepime. Interestingly, doripenem was more
efficacious against both pathogens. Against K. pneumoniae,
doripenem led to a decrease in the bacterial titre of
5.40+1.37 log10 cfu/mL after 8 h versus 3.59+0.89 log10 cfu/mL
for cefepime. The difference was not significant due to the higher
standard deviation in the doripenem group. Doripenemmanaged
to sterilize 5 of 10 CSF samples versus 2 of 10 for cefepime.
Against E. coli, the difference between doripenem and
cefepime was slightly more pronounced, but not significant.
Doripenem managed to sterilize 7 of 10 CSF samples versus 2
of 10 for cefepime.
In summary, this study showed that doripenem, based on its
bactericidal activity and good penetration into the CSF, might be
a very promising option in the treatment of meningitis caused by
nosocomial pathogens, although this disease is not very
common. Thanks to its very low seizure potential21 and its high
efficacy against usual community-acquired pathogens (i.e.
pneumococci), doripenem could be an interesting modality in
the empirical treatment of community-acquired bacterial
meningitis.
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